sfreak49 said:
I am a diagnosed clinically depressed individual. I was wondering what health risks are posed by using thermorexin while taking SSRI's. I noticed on the bottle it doesn't recommend it. Further clarification would be appreciated.
this is mainly due to the yohimbine content (yohimbine is an MAO-i). Anti-depressant are contra-indicated (by their manufacturers) from being used with MAO-i.
note- there are a number of people that use thermorexin with SSRI's, but it cannot be reccomended by the manufacturer because it contains yohimbine.
if you decide to take thermorexin, do not take it at the same time as your medication. Yohimbine is a short acting MAO-i.
you might want to look at Cardio Breeze, it is yohimbine free.
note- there is clinical evidence that yohimbine may actually have a positive interaction with anti-depressants
Neuropsychopharmacology. 2004 Jun;29(6):1166-71. Related Articles, Links
Addition of the alpha2-antagonist yohimbine to fluoxetine: effects on rate of antidepressant response.
Sanacora G, Berman RM, Cappiello A, Oren DA, Kugaya A, Liu N, Gueorguieva R, Fasula D, Charney DS.
Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA.
[email protected]
Electrophysiological studies suggest that alpha2-adrenoceptors profoundly affect monoaminergic neurotransmission by enhancing noradrenergic tone and serotonergic firing rates. Recent reports suggest that alpha2-antagonism may hasten and improve the response to antidepressant medications. To test this hypothesis, a randomized double-blind controlled trial was undertaken to determine if the combination of an alpha2-antagonist (yohimbine) with a selective serotonin reuptake agent (SSRI) (fluoxetine) results in more rapid onset of antidepressant action than an SSRI agent alone. In all, 50 subjects with a DSM-IV diagnosis of major depressive disorder confirmed by SCID interview were randomly assigned to receive either fluoxetine 20 mg plus placebo (F/P) or fluxetine 20 mg plus a titrated dose of yohimbine (F/Y). The yohimbine dose was titrated based on blood pressure changes over the treatment period, in a blind-preserving manner. Hamilton depression scale ratings (HDRS) and clinical global impression (CGI) ratings were obtained weekly over a period of 6 weeks. The rate of achieving categorical positive responses was significantly more rapid in the F/Y group compared to the F/P group using both the HDRS and the CGI scales as outcome measures in a survival analysis using a log-rank test (chi2(1) = 5.86, p = 0.016 and chi2(1) = 5.29, p = 0.021, respectively). At the last observed visit, 18 (69%) of the 26 F/Y subjects met the response criteria for CGI compared to 10 (42%) of 24 F/P subjects. Using the HDRS criteria, 17 (65%) of 26 F/Y subject vs 10 (42%) of 24 F/P subjects were responders. The addition of the alpha2-antagonist yohimbine to fluoxetine appears to hasten the antidepressant response. There is also a trend suggesting an increased percentage of responders to the combined treatment at the end of the 6-week trial. Copyright 2004 Nature Publishing Group
Please Scroll Down to See Forums Below 
